Research Article

Effects of continuous positive airway pressure on plasma fibrinogen levels in obstructive sleep apnea patients: a systemic review and meta-analysis

Juan Lin1,2, Suxian Hu1, Yonghong Shi1, Fang Lu1,2, Wen Luo1,2 and Yihua Lin1,2

1Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China; 2Department of Clinical Medicine, Fujian Medical University, Fuzhou, Fujian, China

Correspondence: Yihua Lin (lyh7@xmu.edu.cn)

Objective: Fibrinogen has been implicated to play a role in the pathophysiology of obstructive sleep apnea (OSA). Many studies have evaluated the effect of continuous positive airway pressure (CPAP) on plasma fibrinogen levels in OSA patients. However, results from different reports were not consistent. To assess the effect of CPAP treatment on plasma fibrinogen levels of patients with OSA, a meta-analysis was performed.

Methods: A systematic search of Pubmed, Embase, Cochrane, Wanfang Database and Chinese National Knowledge Infrastructure was performed. Data were extracted, and then weighted mean difference (WMD) and 95% confidence intervals (CIs) were calculated using a random-effects model.

Results: Twenty-two studies involving 859 patients were included in this meta-analysis. Combined data showed that plasma fibrinogen concentrations decreased after CPAP therapy (WMD = −0.38 g/l, 95% CI [−0.54 to −0.22 g/l], P < 0.001). In the subgroup analyses by therapy duration, plasma fibrinogen concentrations declined significantly in the long-term (≥1 month) CPAP therapy subgroup (WMD = −0.33 g/l, 95% CI [−0.49 to −0.16 g/l], P < 0.001) but not in the short-term (<1 month) CPAP therapy subgroup (WMD = −0.84 g/l, 95% CI [−1.70 to 0.03 g/l], P = 0.058). Moreover, in patients with long-term CPAP therapy duration, plasma fibrinogen levels decreased with good CPAP compliance (≥4 h/night) (WMD = −0.37 g/l, 95% CI [−0.55 to −0.19 g/l], P < 0.001) but not with poor CPAP compliance (<4 h/night) (WMD = 0.12 g/l, 95% CI [−0.09 to 0.33 g/l], P = 0.247).

Conclusion: Long-term CPAP treatment with good compliance can reduce the plasma fibrinogen levels in patients with OSA.

Introduction

Obstructive sleep apnea (OSA), currently characterized by the presence of recurrent episodes of partial or complete upper-airway collapse during sleeping, is a highly prevalent sleep disorder in developed countries [1]. Emerging data showed that patients with OSA have increased risks for cardiovascular diseases (CVDs) [2], which are associated with increased OSA mortalities [3].

The prothrombotic state is one of the important pathways connecting OSA with CVD [4]. The plasma fibrinogen plays a key role in thrombogenesis [5]. According to the Fibrinogen Studies Collaboration, a long-term increase of 1 g/l in fibrinogen level is associated with an approximate doubling risk of major CVDs in a wide range of circumstances in healthy middle-aged adults [6]. Moreover, the plasma fibrinogen concentrations are elevated in patients with OSA and associated with the severity of OSA [7–9]. So the elevated fibrinogen levels may be an important link between OSA and CVD.
Continuous positive airway pressure (CPAP), which eliminates arterial oxyhemoglobin desaturation and hypercapnia [10], is the most effective treatment of OSA [11]. Therapy with CPAP is associated with significant benefits to cardiovascular morbidity and mortality in OSA patients [12]. Moreover, CPAP has displayed remarkable values on improving hypercoagulability in OSA patients [13]. Several studies have assessed the effect of CPAP treatment on circulating fibrinogen concentrations in OSA patients. However, results from different reports were not consistent. Meanwhile, some studies were conducted on a small size, and therefore may not be able to provide sufficient evidence. In order to better evaluate the effects of CPAP on plasma fibrinogen levels in OSA patients, a systematic review and meta-analysis was performed.

Methods

Literature sources and search strategy

Two investigators (Juan Lin and Suxian Hu) searched PubMed, Embase, Cochrane, Wanfang Database and Chinese National Knowledge Infrastructure (CNKI) databases up to 11 October 2020 to identify potentially relevant articles independently. Disagreements were resolved via discussion or adjudicated by a third author (Yihua Lin). The following search terms were used: ‘sleep apnea, obstructive’ [Mesh] OR ‘sleep apnea syndromes’ [Mesh] OR ‘obstructive sleep apnoea’ [Title/Abstract] OR ‘obstructive sleep apnea’ [Title/Abstract]) and ‘fibrinogen’ [Title/Abstract]
Inclusion and exclusion criteria
The studies were included if they met the following items:

1. All participants included in the study were adults.
2. The diagnosis of OSA was apnea hypopnea index (AHI) \( \geq 5 \) events/h by full-night polysomnography.
3. The subjects did not receive any treatment before.
4. All subjects underwent CPAP treatment in the study.
5. Plasma concentrations of fibrinogen in the subjects were measured before and after CPAP treatment.
Figure 3. The forest plot of plasma fibrinogen concentrations in OSA patients with long-term CPAP therapy duration (≥1 month) or short-term CPAP therapy duration (<1 month)

The studies were excluded if they met the following items:

1. Not enough original data.
2. Conferences or case reports.
3. The article was not written in English or Chinese.

Quality assessment

In order to assess the methodological quality of included studies, articles were classified according to levels of evidence (LOE) by using criteria developed by DynaMed’s evidence-based methodology for interventional conclusion [14].

1. Level 1 (likely reliable) evidence represents research results that address clinical outcomes and meet an extensive set of quality criteria that minimizes bias.
2. Level 2 (mid-level) evidence represents research results that address clinical outcomes and demonstrate some methods of scientific investigation but do not meet the quality criteria to achieve Level 1.

3. Level 3 (lacking direct) evidence represents either of the following:
   (a) Reports that are not based on scientific analysis of clinical outcomes (e.g., case series, case reports, conclusions extrapolated indirectly from scientific studies).
   (b) Research results that do not address clinical outcomes, regardless of the scientific rigor.

Data extraction
The data were extracted independently by two investigators (Juan Lin and Suxian Hu) and a consensus was reached on all items. Disagreements were resolved as described above. The following information was extracted: first author, year of publication, country, sample size, body mass index (BMI), gender, age, comorbidities, AHI, severity of OSA,
therapy duration, CPAP time (h/night), plasma fibrinogen levels before and after CPAP treatment displayed by mean and standard deviation (SD). Standard error of mean (SEM) was transformed into SD using statistical formulas [15].

**Statistical analysis**

The data were analyzed using STATA (Stata Corp. 2015. Stata Statistical Software: Release 14. College Station, TX: Stata Corp LP.). The effects of CPAP treatment on plasma fibrinogen concentrations in OSA patients were evaluated. I² values were used to quantify heterogeneity [16]. The random-effects model was adopted if P ≤ 0.10 or I² ≥ 50%, which indicated that the included studies were moderately or highly heterogeneous; otherwise, the fixed-effects model was used. Sensitivity analysis and subgroup analysis was performed to identify the reason of heterogeneity [17]. Egger’s test, Begg’s test and funnel plot were used to assess the publication bias [18].

**Results**

**Study inclusion and characteristics**

The procedure for identifying and selecting eligible studies is shown in Figure 1. A total of 136 articles were retrieved after initial search. Among them, 40 duplicate records were removed, leaving 96 papers for screening. Twenty-one records were excluded based on titles and abstracts and one paper was excluded for being in French. And then 52 records were excluded after full-text review for various reasons. Among them, 35 papers were excluded for conference or review, 5 papers had no relevant outcomes, 10 papers had not enough original data, and 2 papers did not use CPAP. Finally, 22 articles were included for this meta-analysis, containing 859 OSA patients in total [19–40]. Among them, 16 articles were from China [19,21,26–38,40]. In the included studies, the severity of OSA contained mild to moderate [32,38], moderate to severe [19,22,23,26,27,29–32,34,36,37,39], severe [20,21,24] and uncategorized [25,28,33,35,40]. The duration of CPAP therapy in eligible studies was categorized into short-term (<1 month) [19,23,33,40] and long-term (≥1 month) [19–22,24–32,34–39]. In the long-term CPAP treatment group, the patients received CPAP treatment for different hours every night, which were divided into good compliance (≥4 h/night)
Figure 6. The forest plot of plasma fibrinogen concentrations before and after CPAP treatment in OSA patients with or without comorbidities

[19–22,24–31,34–39], poor compliance (<4 h/night) [20,21,39] and no mention of time [32]. In the short-term CPAP treatment group, the patients received CPAP treatment for different hours every night, which were also divided into good compliance (≥4 h/night) [19,23,40] and no mention of time [33]. In terms of comorbidities, 4 articles recruited OSA patients with comorbidities [21,23,29,32], 15 articles recruited OSA patients without comorbidities [19,20,24,27,28,30,31,33–40], 1 article recruited both patients with comorbidities and patients without comorbidities [25], and the remaining 2 articles did not mention patients’ comorbidities [22,26]. According to the severity of OSA, the term of CPAP treatment, the compliance of CPAP treatment and comorbidities, 22 articles were divided into 32 studies. All studies had an LOE score of 2. The main characters of all the included studies are presented in Tables 1 and 2.
Figure 7. Funnel plots for evaluation of publication bias in the included studies

Quantitative analysis
The pooled effect size showed that the plasma fibrinogen concentrations of OSA patients decreased significantly after CPAP treatment (weighted mean difference (WMD) = −0.38 g/l, 95% confidence interval (CI) [−0.54 to −0.22 g/l], P < 0.001; I² = 96.6%, P < 0.001; Figure 2). In the subgroup analyses by therapy duration, plasma fibrinogen concentrations declined significantly in the long-term (≥1 month) CPAP therapy subgroup (WMD = −0.33 g/l, 95% CI [−0.49 to −0.16 g/l], P < 0.001; I² = 96.6%, P < 0.001; Figure 3) but not in the short-term (<1 month) CPAP therapy subgroup (WMD = −0.84 g/l, 95% CI [−1.70 to 0.03 g/l], P = 0.058; I² = 95.2%, P < 0.001; Figure 3). Moreover, in OSA patients treated with long-term CPAP, fibrinogen level decreased only in patients with good CPAP compliance (≥4 h/night) (WMD = −0.37 g/l, 95% CI [−0.55 to −0.19 g/l], P < 0.001; I² = 97.2%, P < 0.001; Figure 4), but not in those with poor CPAP compliance (<4 h/night) (WMD = −0.12 g/l, 95% CI [−0.09 to 0.33 g/l], P = 0.247; I² = 0.0%, P = 0.763; Figure 4). In the short-term CPAP treatment group, fibrinogen level did not decrease significantly, even in those with good CPAP compliance (WMD = −0.65 g/l, 95% CI [−1.70 to 0.40 g/l], P = 0.223; I² = 96.7%, P < 0.001; Figure 5). In another subgroup analyses by comorbidities, plasma fibrinogen concentrations declined significantly in patients without comorbidities (WMD = −0.44 g/l, 95% CI [−0.58 to −0.21 g/l], P < 0.001; I² = 96.8%, P < 0.001; Figure 6) but not in patients with comorbidities (WMD = −0.24 g/l, 95% CI [−0.75 to 0.27 g/l], P = 0.364; I² = 94.4%, P < 0.001; Figure 6).

Sensitivity analysis
We performed sensitivity analyses for all the results. The observed significant results were not materially altered after we sequentially excluded each study.
which deviated the furthest, the conclusions remained the same.

Moreover, after excluding the five studies demonstrated that there was no evidence to confirm publication bias in the study. Moreover, after excluding the five studies which deviated the furthest, the conclusions remained the same.

Publication bias
The funnel plot seemed unsymmetrical (Figure 7). However, Begg’s test ($P=0.638$) and Egger’s test ($P=0.231$) demonstrated that there was no evidence to confirm publication bias in the study. Moreover, after excluding the five studies [29,30,33,35,40] which deviated the furthest, the conclusions remained the same.

Discussion
The present study conducted a systemic review and meta-analysis to investigate the efficacy of CPAP on fibrinogen levels in patients with OSA. To the best of our knowledge, this is the first systematic review and meta-analysis to assess the effect of CPAP treatment on plasma fibrinogen in OSA patients. The important finding of the present study is that long-term CPAP treatment with good compliance can reduce the plasma fibrinogen levels in patients with OSA.

In OSA patients, fibrinogen levels are elevated [41,42], even after adjusting for comorbidities such as arterial hypertension or coronary artery disease [43]. Moreover, the concentration of fibrinogen has been found to be directly related to severity of OSA patients [8]. However, the exact mechanism related to OSA and fibrinogen was not fully clear. It is well known that OSA is characterized by chronic persistent hypoxia, chronic intermittent hypoxia and sleep disturbance, which is related to increased reactive oxygen species (ROS) and oxidative stress response. Fibrinogen, which is in response to inflammation and ROS, affects blood coagulation, hemorheology and platelet aggregation, and

### Table 1 Characteristics of studies included in the meta-analysis

| Study (first author, year) | Country          | Sample size | BMI (kg/m²) | Gender | Age  | Comorbidities                  | LOE |
|----------------------------|------------------|-------------|-------------|--------|------|-------------------------------|-----|
| Chin K., 1996              | Japan            | 11          | 31.10 ± 5.30| ND     | 48.20 ± 12.80 | Two hypertension patients | 2   |
| Chin K., 1998              | Japan            | 15          | 31.10 ± 5.03| males  | 45.30 ± 12.00 | ND               | 2   |
| Du X., 2003                | China            | 38          | 28.80 ± 2.10| males  | 50.40 ± 10.80 | Exclude chronic disease | 2   |
| Su M., 2003                | China            | 13          | 26.40 ± 3.20| males  | 51.00 ± 6.30 | Exclude chronic disease | 2   |
| Zhang X., 2003             | China            | 41          | 26.90 ± 3.00| males, females | 63.40 ± 4.00 | ND               | 2   |
| Zhang X., 2003-1a          | China            | 16          | 27.00 ± 3.00| males, females | 41.00–65.00 | Exclude chronic disease | 2   |
| Zhang X., 2003-1b          | China            | 16          | 27.00 ± 3.00| males, females | 41.00–65.00 | Exclude chronic disease | 2   |
| Zhang X., 2003-2a          | China            | 16          | 26.70 ± 3.10| males, females | 64.00 ± 4.10 | Exclude chronic disease | 2   |
| Zhang X., 2003-2b          | China            | 16          | 26.70 ± 3.10| males, females | 64.00 ± 4.10 | Exclude chronic disease | 2   |
| Zhang X., 2004             | China            | 16          | 26.7 ± 3.10 | males, females | 50.00 ± 6.00 | Exclude chronic disease | 2   |
| Dorkova Z., 2008a          | Slovak Republic  | 16          | 32.80 ± 4.40| males | 51.30 ± 9.50 | Exclude chronic disease | 2   |
| Dorkova Z., 2008b          | Slovak Republic  | 15          | 37.30 ± 6.90| males | 56.10 ± 9.50 | Exclude chronic disease | 2   |
| Chen X., 2010              | China            | 40          | 26.80 ± 4.30| males, females | 47.40 ± 5.90 | Exclude chronic disease | 2   |
| Feng J., 2010              | China            | 30          | ND          | males, females | 54.30 ± 11.60 | Exclude chronic disease | 2   |
| Kumor M., 2011a            | Poland           | 16          | 30.40 ± 3.80| ND     | 54.20 ± 6.90 | With IHD          | 2   |
| Kumor M., 2011b            | Poland           | 24          | 30.30 ± 2.80| ND     | 50.00 ± 9.80 | Exclude chronic disease | 2   |
| Zhang X., 2011a            | China            | 15          | ND          | males, females | 55.00–75.00 | Exclude chronic disease | 2   |
| Zhang X., 2011b            | China            | 15          | ND          | males, females | 55.00–75.00 | Exclude chronic disease | 2   |
| Zhang X., 2011c            | China            | 15          | ND          | males, females | 55.00–75.00 | Exclude chronic disease | 2   |
| Xu D., 2012                | China            | 85          | ND          | ND     | 31.00–55.00 | Exclude chronic disease | 2   |
| Ni L., 2014a               | China            | 24          | 30.40 ± 3.80| ND     | ND     | Exclude chronic disease       | 2   |
| Ni L., 2014b               | China            | 16          | 30.30 ± 2.80| ND     | ND     | Exclude chronic disease       | 2   |
| Xu J., 2014a               | China            | 33          | 31.82 ± 5.60| ND     | 13 hypertension, 6 diabetes   | 2   |
| Xu J., 2014b               | China            | 17          | 36.50±4.36  | ND     | 9 hypertension, 5 diabetes    | 2   |
| Zhang X., 2014a            | China            | 34          | ND          | ND     | ND     | With IHD                      | 2   |
| Zhang X., 2014b            | China            | 11          | ND          | ND     | ND     | With IHD                      | 2   |
| Wang H., 2015              | China            | 48          | ND          | ND     | ND     | With IHD                      | 2   |
| Kisabay A., 2016           | Turkey           | 65          | 29.43 ± 2.33| males, females | 48.23 ± 11.17 | Exclude chronic disease | 2   |
| Kimihiko M., 2020a         | Japan            | 27          | 27.50 ± 4.10| males, females | 60.00 ± 9.00 | Exclude chronic disease       | 2   |
| Kimihiko M., 2020b         | Japan            | 33          | 28.50 ± 4.30| males, females | 56.00 ± 11.00 | Exclude chronic disease       | 2   |
| Wang Z., 2020              | China            | 40          | 25.81 ± 1.16| males, females | 52.37 ± 6.14 | Exclude chronic disease       | 2   |
| Xu Y., 2020                | China            | 42          | ND          | males, females | 58.71 ± 8.34 | Exclude chronic disease       | 2   |

Abbreviations: IHD, ischemic heart disease; ND, no data.
Table 2 The characteristics of studies included in the meta-analysis

| Study (first author, year) | AHI     | Severity          | CPAP duration       | Daily duration (h/night) | Fibrinogen levels (mean ± SD) |
|---------------------------|---------|-------------------|---------------------|--------------------------|-------------------------------|
|                           |         |                   |                     |                          | Pre-CPAP (g/l) | Post-CPAP (g/l) |
| Chin K., 1996            | 62.90 ± 20.90 | Moderate to severe | 1 day               | ≥6                       | 2.98 ± 0.53 | 2.76 ± 0.37 |
| Chin K., 1998            | 61.50 ± 16.30 | Moderate to severe | 6 months            | ≥5                       | 2.99 ± 0.62 | 2.92 ± 0.66 |
| Du X., 2003              | 56.00 ± 22.00 | Mild to severe     | 1 day               | ND                       | 5.43 ± 1.59 | 3.98 ± 1.37 |
| Su M., 2003              | ≥15     | Moderate to severe | 1 month             | 6–8                      | 2.75 ± 0.13 | 2.74 ± 0.14 |
| Zhang X., 2003           | 37.40 ± 9.60 | Moderate to severe | 1 month             | 6–8                      | 2.96 ± 0.14 | 2.77 ± 0.15 |
| Zhang X., 2003-1a        | ≥15     | Moderate to severe | 1 month             | 6–8                      | 2.77 ± 0.12 | 2.75 ± 0.13 |
| Zhang X., 2003-1b        | ≥15     | Moderate to severe | 1 month             | 6–8                      | 2.97 ± 0.12 | 2.76 ± 0.12 |
| Zhang X., 2003-2a        | 39.90 ± 11.50 | Moderate to severe | 1 month             | 6–8                      | 2.80 ± 12.00 | 2.80 ± 13.00 |
| Zhang X., 2003-2b        | 39.90 ± 11.50 | Moderate to severe | 1 month             | 6–8                      | 3.00 ± 12.00 | 2.70 ± 12.00 |
| Zhang X., 2004           | ≥15     | Moderate to severe | 1 month             | ≥6                       | 2.97 ± 0.12 | 2.76 ± 0.12 |
| Dorkova Z., 2008a        | 64.70 ± 23.30 | Severe             | 2 months            | ≥4                       | 3.16 ± 0.99 | 3.45 ± 0.89 |
| Dorkova Z., 2008b        | 63.20 ± 18.80 | Severe             | 2 months            | ≥4                       | 3.43 ± 0.68 | 3.48 ± 0.93 |
| Chen X., 2010            | ≥5      | Mild to severe     | 1 month             | 6–8                      | 3.87 ± 0.51 | 2.43 ± 0.26 |
| Feng J., 2010            | 55.10 ± 10.20 | Moderate to severe | 6 months            | 6–8                      | 3.95 ± 0.75 | 3.21 ± 0.45 |
| Kumor M., 2011a          | 48.30 ± 20.30 | Mild to severe     | 3 months            | 4.40 ± 1.80              | 3.50 ± 0.88 | 3.68 ± 1.05 |
| Kumor M., 2011b          | 45.40 ± 21.50 | Mild to severe     | 3 months            | 4.40 ± 1.80              | 3.11 ± 0.53 | 3.28 ± 0.71 |
| Zhang X., 2011a          | ≥15     | Moderate to severe | 15 days             | 6–8                      | 3.00 ± 0.58 | 2.89 ± 0.45 |
| Zhang X., 2011b          | ≥15     | Moderate to severe | 1 month             | 6–8                      | 3.00 ± 0.58 | 2.86 ± 0.54 |
| Zhang X., 2011c          | ≥15     | Moderate to severe | 3 months            | 6–8                      | 3.00 ± 0.58 | 2.22 ± 0.33 |
| Xu D., 2012              | ≥15     | Moderate to severe | 1 month             | 6–8                      | 6.20 ± 1.10 | 3.40 ± 0.70 |
| Ni L., 2014a             | 48.30 ± 20.30 | Mild to severe     | 3 months            | 5.20 ± 1.50              | 3.50 ± 0.88 | 3.68 ± 1.05 |
| Ni L., 2014b             | 45.40 ± 21.50 | Mild to severe     | 3 months            | 4.40 ± 1.80              | 3.11 ± 0.54 | 3.28 ± 0.71 |
| Xu J., 2014a             | 64.40 ± 16.00 | Severe             | 10 weeks            | ≥4                       | 3.12 ± 0.68 | 3.29 ± 0.61 |
| Xu J., 2014b             | 63.40 ± 15.40 | Severe             | 10 weeks            | <4                       | 3.23 ± 0.58 | 3.45 ± 0.40 |
| Zhang X., 2014a          | ≥15     | Moderate to severe | 2 months            | ND                       | 3.53 ± 0.97 | 2.99 ± 0.82 |
| Zhang X., 2014b          | <15     | Mild               | 2 months            | ND                       | 2.40 ± 0.56 | 2.10 ± 0.46 |
| Wang H., 2015            | ≥15     | Moderate to severe | 1 month             | 8                        | 2.94 ± 0.28 | 1.87 ± 0.36 |
| Kisabay A., 2016         | ≥30     | Severe             | 3 months            | 5.60                     | 3.45 ± 0.76 | 3.15 ± 0.49 |
| Kimihiko M., 2020a       | 39.20 ± 25.70 | Moderate to severe | 3 months            | 5.70 ± 0.80              | 2.75 ± 0.46 | 2.55 ± 0.47 |
| Kimihiko M., 2020b       | 43.30 ± 28.89 | Moderate to severe | 3 months            | 3.10 ± 1.00              | 2.77 ± 0.62 | 2.84 ± 0.70 |
| Wang Z., 2020            | 35.26 ± 4.36 | Mild to moderate   | 1 month             | ≥5                       | 3.03 ± 0.33 | 2.67 ± 0.29 |
| Xu Y., 2020              | 26.23 ± 7.25 | Mild to severe     | 2 weeks             | ≥4                       | 4.53 ± 0.66 | 2.93 ± 0.47 |

Abbreviation: ND, no data.

promotes the progress of atherosclerosis [44]. Plasma fibrinogen elevation in OSA patients may be due to the combined effects of OSA-induced disturbances in biochemical neurohumoral regulation, inflammation and metabolism [45].

CPAP treatment can improve OSA associated hypoxia condition and oxidative stress. It is now accepted as the standard and ‘first-line’ treatment in current management of OSA [10]. The results of our study showed that CPAP treatment can reduce the plasma fibrinogen levels in OSA patients, which is in accordance with the previous studies of Kisabay et al. [24] and Feng et al. [27]. In the subgroup analyses, long-term CPAP therapy with good compliance can reduce the plasma fibrinogen levels, while long-term CPAP therapy with poor compliance or short-term CPAP therapy did not. This result should be attributed to the fact that long-term CPAP therapy with good compliance can improve hypoxia condition and oxidative stress in OSA patients better than short-term CPAP therapy or poor compliance.

Reducing fibrinogen levels in OSA patients might have potential important clinical implications. Fibrinogen enhances thrombosis and atherosclerosis via its effects on platelet aggregation, blood rheology and endothelial-cell injury [5]. Meanwhile, fibrinogen and its degradation products may further damage blood vessels by stimulating smooth muscle proliferation and migration [46,47]. A systemic review has confirmed the significance of elevated fibrinogen for prediction of future cardiovascular risk even in the healthy, middle-aged population [48]. Hence fibrinogen has...
been acknowledged as an important biomarker for cardiovascular risk [43,49], and may be responsible for the high incidence of CVD in OSA patients [50]. Therefore, CPAP may reduce cardiovascular mortality in OSA patients by reducing fibrinogen levels, which is in accordance with the study of Aslan et al. [51]. So, our study provided a robust evidence that once OSA is diagnosed, a long-term CPAP therapy with good compliance should be applied as soon as possible.

However, in OSA patients with comorbidities, the levels of fibrinogen did not decrease significantly after CPAP treatment. This may be due to both comorbidities [6] and OSA [7] can lead to elevated plasma fibrinogen levels, while CPAP can only improve the pathological condition of OSA. Thus, in addition to CPAP therapy, extra pharmacological treatment may be needed to treat comorbidities in OSA patients.

Several limitations still existed in our research. The heterogeneity test showed that there was heterogeneity among the studies, because many confounding factors may coexist in OSA patients. We failed to explore the reason of heterogeneity by subgroup analysis based on CPAP therapy duration (<1 and ≥1 month), CPAP daily duration (<4 and ≥4 h/night) and comorbidities. Moreover, in most of the included studies, the severity of OSA were moderate to severe, we did not perform subgroup analysis based on OSA severity.

Conclusion
This meta-analysis indicates that CPAP treatment, especially with long-term and good compliance, can reduce plasma fibrinogen concentrations in OSA patients.

Data Availability
All the data used and/or analyzed during the current study can be obtained by contacting the corresponding author on reasonable request.

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.

Funding
This work was supported by the Youth Scientific Research Project of Fujian Provincial Health Commission and Xiamen Municipal Health Commission in China [grant number 2016-2-64].

Author Contribution
Yihua Lin designed the study and revised the manuscript. Juan Lin conducted literature search, data analysis and drafted the manuscript. Suxian Hu conducted literature search, data analysis. Yonghong Shi, Fang Lu and Wen Luo conducted data analysis. All the authors read and approved the final manuscript.

Acknowledgements
The authors would like to thank the Fujian Provincial Health Commission and Xiamen Municipal Health Commission for their support in this research.

Abbreviations
AHI, apnea hypopnea index; CI, confidence interval; CPAP, continuous positive airway pressure; CVD, cardiovascular disease; LOE, level of evidence; OSA, obstructive sleep apnea; ROS, reactive oxygen species; SD, standard deviation; WMD, weighted mean difference.

References
1 Drager, L.F., McEvoy, R.D., Barbe, F., Lorenzi-Filho, G. and Redline, S. (2017) Sleep apnea and cardiovascular disease: lessons from recent trials and need for team science. Circulation 136, 1840–1850, https://doi.org/10.1161/CIRCULATIONAHA.117.029400
2 Badran, M., Yassin, B.A., Fox, N., Laher, I. and Ayas, N. (2015) Epidemiology of sleep disturbances and cardiovascular consequences. Can. J. Cardiol. 31, 873–879, https://doi.org/10.1016/j.cjca.2015.03.011
3 He, J., Kryger, M.H., Zorick, F.J., Conway, W. and Roth, T. (1988) Mortality and apnea index in obstructive sleep apnea. Experience in 385 male patients. Chest 94, 9–14, https://doi.org/10.1378/chest.94.1.9
4 von Kanel, R. andDimsdale, J.E. (2003) Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. Chest 124, 1956–1967, https://doi.org/10.1378/chest.124.5.1956
34 Zhang, X.L., Yin, K.S., Su, M. et al. (2003) Effect of continuous positive airway pressure on prethrombotic state in elderly patients with obstructive sleep apnea syndrome. *Chinese J. Geriatrics* **22**, 29–31, (Chinese)

35 Chen, X.K. and Sheng, C.Y. (2010) Effect of continuous positive airway pressure ventilation on platelet activating factor and blood coagulation function in patients with obstructive sleep apnea-hypopnea syndrome. *Labeled Immunoassays Clin. Med.* **17**, 212–4, (Chinese)

36 Su, M., Yin, K.S. and Zhang, X.L. (2003) Effect of positive nasal airway pressure on risk factors of thrombus in obstructive sleep apnea syndrome. *J. Nanjing Med. Univ. (Nat. Sci. Ed.)* **23**, 283–4, (Chinese)

37 Zhang, X.L., Yin, K.S., Su, M. et al. (2003) Effect of positive pressure ventilation on thrombus formation in patients with obstructive sleep apnea hypopnea syndrome. *Chinese J. Tubercul. Respir. Dis.* **26**, 54, (Chinese)

38 Wang, Z., Sun, L.J., Feng, M.M. et al. (2020) Effect of Xiaona Li Qi Prescription on plasma fibrinogen, inflammatory factors, C-reactive protein and oxidative stress in patients with phlegm-dampened obstructive sleep apnea hypopnea syndrome. *Hebei J. Tradit. Chin. Med.* **42**, 842–847, (Chinese)

39 Murase, K., Azuma, M., Tachikawa, R. et al. (2020) Prospective associations of sleep apnea, periodic limb movements, and plasma fibrinogen level. *Sleep Breath.*, https://doi.org/10.1007/s11325-020-02147-5

40 Xu, Y.F., Li, Y.L., Chen, J.M. et al. (2020) Effects of continuous positive airway pressure ventilation on vascular endothelium and fibrinolysis in patients with obstructive sleep apnea syndrome. *China Med. Med.* **7**, 39–44, (Chinese)

41 Peled, N., Kassirer, M., Kramer, M.R., Rogowski, O., Shlomi, D., Fox, B. et al. (2008) Increased erythrocyte adhesiveness and aggregation in obstructive sleep apnea syndrome. *Thromb. Res.* **121**, 631–636, https://doi.org/10.1016/j.thromres.2007.07.010

42 Wessendorf, T.E., Thilmann, A.F., Wang, Y.M., Schreiber, A., Konietzko, N. and Teschler, H. (2000) Fibrinogen levels and obstructive sleep apnea in ischemic stroke. *Am. J. Respir. Crit. Care Med.* **162**, 2039–2042, https://doi.org/10.1164/ajrccm.162.6.20001048

43 Steiner, S., Jax, T., Evers, S., Hennersdorf, M., Schwalen, A. and Strauer, B.E. (2005) Altered blood rheology in obstructive sleep apnea as a mediator of cardiovascular risk. *Cardiology* **104**, 92–96, https://doi.org/10.1159/000086729

44 Cerit, L. (2017) Fibrinogen and atherosclerosis. *Arq. Bras. Cardiol.* **108**, 189–190, https://doi.org/10.5935/abc.20170017

45 von Kanel, R. andDimsdale, J.E. (2003) Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. *Chest* **124**, 1956–1967, https://doi.org/10.1378/chest.124.5.1956

46 Lee, A.J., Smith, W.C., Lowe, G.D. and Tunstall-Pedoe, H. (1990) Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. *J. Clin. Epidemiol.* **43**, 913–919, https://doi.org/10.1016/0895-4356(90)90075-Z

47 Smith, E.B., Keen, G.A., Grant, A. and Stirk, C. (1990) Fate of fibrinogen in human arterial intima. *Arteriosclerosis* **10**, 263–275, https://doi.org/10.1161/01.ATV.10.2.263

48 Kaptoge, S., Di Angelantonio, E., Pennellis, L., Wood, A.M., White, I.R., Gao, P. et al. (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. *N. Engl. J. Med.* **367**, 1310–1320, https://doi.org/10.1056/NEJMoa1107477

49 Palmieri, V., Colantano, A., Roman, M.J., de Simone, G., Best, L., Lewis, M.R. et al. (2003) Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study. *Am. Heart J.* **145**, 467–474, https://doi.org/10.1016/S0002-8703(03)00402-0

50 Parati, G., Lombardi, C. and Narkiewicz, K. (2007) Sleep apnea: epidemiology, pathophysiology, and relation to cardiovascular risk. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **293**, R1671–R1683, https://doi.org/10.1152/ajpregu.00400.2007

51 Aslan, G., Afsar, B., Sirinopol, D., Kanbay, A., Sal, O., Benli, C. et al. (2018) Cardiovascular effects of continuous positive airway pressure treatment in patients with obstructive sleep apnea: a meta-analysis. *Angiology* **69**, 195–204, https://doi.org/10.1177/0003319717709175